Management of Gastrointestinal Bleeding in Patients on Triple Antithrombotic Therapy After PCI

Immediate Assessment and Management

The American Heart Association recommends obtaining a complete blood count immediately to assess for anemia and quantify blood loss in patients with dark stool on triple therapy, as this represents presumed GI bleeding until proven otherwise 1, 3
The American College of Cardiology suggests checking hemodynamic stability, including blood pressure, heart rate, and signs of active bleeding, in patients with suspected GI bleeding on triple antithrombotic therapy 1
Assessment of timing from PCI is crucial to determine whether the patient is still in the critical period requiring dual antiplatelet therapy or can safely de-escalate, according to the American College of Chest Physicians 4, 2

The American College of Cardiology recommends stopping aspirin immediately while maintaining rivaroxaban and ticagrelor as double therapy in patients with confirmed bleeding, provided the patient is beyond the immediate peri-PCI period 4, 5, 2
Triple therapy (OAC + aspirin + P2Y12 inhibitor) significantly increases bleeding risk without proportional ischemic benefit beyond the initial post-PCI period, according to the American Heart Association 1, 4
Current guidelines from the American College of Cardiology recommend double therapy (OAC + P2Y12 inhibitor) as the default strategy for most patients after PCI in atrial fibrillation, with aspirin discontinued at or shortly after hospital discharge 2

The European Society of Cardiology suggests arranging urgent upper and lower endoscopy to identify the bleeding source, as this will guide further management and determine if antithrombotic therapy can be safely resumed 1, 6
Upper endoscopy should be performed first given that dark stool (melena) typically indicates upper GI source, according to the European Heart Journal 6

The American College of Cardiology recommends initiating or optimizing PPI therapy immediately with a non-CYP2C19-interfering agent, such as pantoprazole or dexlansoprazole, to reduce GI bleeding risk in patients on oral anticoagulation plus antiplatelet therapy 1, 3
PPI should be considered mandatory in all patients on oral anticoagulation plus antiplatelet therapy to reduce GI bleeding risk, according to the American Heart Association 1, 4, 3

The American College of Chest Physicians advises against discontinuing rivaroxaban unless bleeding is life-threatening or uncontrollable, as this patient requires anticoagulation for atrial fibrillation stroke prevention 4, 5
The stroke risk from untreated atrial fibrillation typically outweighs bleeding risk once the acute bleeding is controlled, according to the American College of Chest Physicians 4

The American College of Chest Physicians suggests considering switching from ticagrelor to clopidogrel if bleeding recurs or is difficult to control, as clopidogrel is the preferred P2Y12 inhibitor when combined with oral anticoagulation due to lower bleeding risk compared to ticagrelor or prasugrel 4, 5

The American College of Cardiology recommends transitioning to double therapy (rivaroxaban + clopidogrel) without aspirin for up to 12 months post-PCI, then rivaroxaban monotherapy 2
At 12 months post-PCI, discontinuing all antiplatelet therapy and continuing rivaroxaban alone at full stroke-prevention dose is recommended, according to the American College of Cardiology 2

The American Heart Association suggests rechecking hemoglobin in 24-48 hours after stopping aspirin to ensure bleeding has stopped, and monitoring for signs of recurrent bleeding and thrombotic complications 1